Development and validation of a risk model with variables related to non-small cell lung cancer in patients with pulmonary nodules: a retrospective study

被引:0
|
作者
Liao, Zufang [1 ]
Zheng, Rongjiong [2 ]
Li, Ni [3 ]
Shao, Guofeng [3 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Ningbo 315041, Zhejiang, Peoples R China
[2] Ningbo Yinzhou 2 Hosp, Ningbo 315192, Zhejiang, Peoples R China
[3] Ningbo Univ, Dept Cardiothorac Surg, Li Huili Hosp, Xingning Rd 57, Ningbo 315041, Zhejiang, Peoples R China
关键词
NSCLC; Pulmonary nodules; Logistic; Variables; Model; GROUND-GLASS OPACITY; SOCIETY GUIDELINES; PROBABILITY; MANAGEMENT; BLOCKERS; TISSUE;
D O I
10.1186/s12885-023-11385-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundLung cancer is a major global threat to public health for which a novel predictive nomogram is urgently needed. Non-small cell lung cancer (NSCLC) which accounts for the main port of lung cancer cases is attracting more and more people's attention.Patients and methodsHere, we designed a novel predictive nomogram using a design dataset consisting of 515 pulmonary nodules, with external validation being performed using a separate dataset consisting of 140 nodules and a separate dataset consisting of 237 nodules. The selection of significant variables for inclusion in this model was achieved using a least absolute shrinkage and selection operator (LASSO) logistic regression model, after which a corresponding nomogram was developed. C-index values, calibration plots, and decision curve analyses were used to gauge the discrimination, calibration, and clinical utility, respectively, of this predictive model. Validation was then performed with the internal bootstrapping validation and external cohorts.ResultsA predictive nomogram was successfully constructed incorporating hypertension status, plasma fibrinogen levels, blood urea nitrogen (BUN), density, ground-glass opacity (GGO), and pulmonary nodule size as significant variables associated with nodule status. This model exhibited good discriminative ability, with a C-index value of 0.765 (95% CI: 0.722-0.808), and was well-calibrated. In validation analyses, this model yielded C-index values of 0.892 (95% CI: 0.844-0.940) for external cohort and 0.853 (95% CI: 0.807-0.899) for external cohort 2. In the internal bootstrapping validation, C-index value could still reach 0.753. Decision curve analyses supported the clinical value of this predictive nomogram when used at a NSCLC possibility threshold of 18%.ConclusionThe nomogram constructed in this study, which incorporates hypertension status, plasma fibrinogen levels, BUN, density, GGO status, and pulmonary nodule size, was able to reliably predict NSCLC risk in this Chinese cohort of patients presenting with pulmonary nodules.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Lower Risk of Hypercoagulability in Non-Small Cell Lung Cancer Patients with EGFR Mutations
    Ohara, S.
    Suda, K.
    Takemoto, T.
    Nishino, M.
    Chiba, M.
    Fujino, T.
    Hamada, A.
    Koga, T.
    Soh, J.
    Misudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S653 - S653
  • [32] Construction and validation of prognostic nomograms for elderly patients with metastatic non-small cell lung cancer
    Sun, Haishuang
    Liu, Min
    Yang, Xiaoyan
    Ren, Yanhong
    Dai, Huaping
    Wang, Chen
    CLINICAL RESPIRATORY JOURNAL, 2022, 16 (05): : 380 - 393
  • [33] Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study
    Degens, Juliette
    De Ruysscher, D.
    Houben, Ruud
    Kietselaer, Bastiaan
    Bootsma, Gerben
    Hendriks, Lizza
    Huijbers, Ellen
    Schols, Annemie
    Dingemans, Anne-Marie C.
    BMJ OPEN, 2020, 10 (09):
  • [34] A retrospective study of volume doubling time in surgically resected non-small cell lung cancer
    Mackintosh, John A.
    Marshall, Henry M.
    Yang, Ian A.
    Bowman, Rayleen V.
    Fong, Kwun M.
    RESPIROLOGY, 2014, 19 (05) : 755 - 762
  • [35] Sintilimab for the treatment of non-small cell lung cancer
    Zhang, Lin
    Lin, Weihao
    Tan, Fengwei
    Li, Ning
    Xue, Qi
    Gao, Shugeng
    Gao, Yibo
    He, Jie
    BIOMARKER RESEARCH, 2022, 10 (01)
  • [36] Is the Outcome of Pulmonary Resections due to Non-Small Cell Lung Cancer in Octogenarian Patients Worse?
    Kutluk, Ali Cevat
    Akin, Hasan
    Ceritoglu, Altan
    Kocaturk, Celalettin Ibrahim
    Bilen, Salih
    Sonmezoglu, Yasar
    Karapinar, Kemal
    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 25 (02) : 95 - 101
  • [37] Development and Validation of a Risk Assessment Model for Pulmonary Nodules Using Plasma Proteins and Clinical Factors
    Vachani, Anil
    Lam, Stephen
    Massion, Pierre P.
    Brown, James K.
    Beggs, Michael
    Fish, Amanda L.
    Carbonell, Luis
    Wang, Shan X.
    Mazzone, Peter J.
    CHEST, 2023, 163 (04) : 966 - 976
  • [38] Results of pneumonectomy in non-small cell lung cancer patients
    Gibas, Artur
    Chwirot, Piotr
    Rzyman, Witold
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 6 (02) : 142 - 148
  • [39] Non-Small Cell Lung Cancer Resection in Lymphoma Patients
    Kim, Min P.
    Correa, Arlene M.
    Swisher, Stephen G.
    Hofstetter, Wayne L.
    Mehran, Reza J.
    Rice, David C.
    Walsh, Garrett L.
    Erasmus, Jeremy, Jr.
    Moran, Cesar
    Vaporciyan, Ara A.
    Roth, Jack A.
    ANNALS OF THORACIC SURGERY, 2010, 90 (01): : 210 - 216
  • [40] A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer
    Ulas, Arife
    Turkoz, Fatma Paksoy
    Silay, Kamile
    Tokluoglu, Saadet
    Avci, Nilufer
    Oksuzoglu, Berna
    Alkis, Necati
    PLOS ONE, 2014, 9 (12):